Research and Markets: Targeted Oncology

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/147efb/targeted_oncology) has announced the addition of Future Science Ltd's new report "Targeted Oncology: Part I" to their offering.

Targeted oncology is a two-part SFI January 04(01) and March 04(04) (yet to be published), guest edited by Prof. David Thurston (King's College London, UK) our UK senior editor: The issue provides a comprehensive, forward-looking overview of current efforts, new insights and significant advances in the design, preparation and evaluation of targeted anti-cancer therapies (including small molecules, macromolecules, polymers, antibodydrug conjugates, nanotechnology approaches) and target identification

Key Topics Covered:

EDITORIAL

• Global financial challenge: opportunities for strengthening R&D research in targeted drug delivery
• US Supreme Court could reshape Hatch-Waxman's same labeling requirement

NEWS & ANALYSIS

• News & Analysis

COMMENTARY

• Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?

REVIEW

• Eukaryotic initiation factor 4F: a vulnerability of tumor cells
• Tumor-targeting drug delivery of new-generation taxoids
• Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes
• Recent advances in the application of antibodies as therapeutics
• Advancing cancer drug discovery towards more agile development of targeted combination therapies
• Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer

ACKNOWLEDGEMENTS

For more information visit http://www.researchandmarkets.com/research/147efb/targeted_oncology